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Abstract
Background: The aggregation of amyloid proteins into fibrils is associated with neurodegenerative diseases such as
Alzheimer’s and Type II Diabetes. Different methods have explored ways to impede and inhibit amyloid aggregation.
Most attempts in the literature involve applying stress to the environment around amyloids. Varying pH levels,
modifying temperature, applying pressure through protein crowding and ligand docking are classical examples of
these methods. However, environmental stress usually affects molecular pathways and protein functions in the cell
and is challenging to construct in vivo. In this paper, we explore destabilizing amyloid proteins through the
manipulation of genetic code to create beneficial substitute molecules for patients with certain deficiencies.
Results: To unravel sequence mutations that destabilize amyloid fibrils yet simultaneously conserve native fold, we
analyze the structural landscape of amyloid proteins and search for potential areas that could be exploited to weaken
aggregation. Our tool, FibrilMutant, analyzes these regions and studies the effect of amino acid point mutations on
nucleation and aggregation. This multiple objective approach impedes aggregation without stressing the cellular
environment. We identified six main regions in amyloid proteins that contribute to structural stability and generated
amino acid mutations to destabilize those regions. Full length fibrils were built from the mutated amyloid monomers
and a dipolar-solvent model capturing the effect of dipole-dipole interactions between water and very large
molecular systems to assess their aqueous stability was used to generate energy plots.
Conclusion: Our results are in agreement with experimental studies and suggest novel targeted single point
mutations in the Amylin protein, potentially creating a better therapeutic agent than the currently administered
Pramlintide drug for diabetes patients.
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Background
Protein misfolding has been regarded as one of the most
important events triggering a wide variety of neurode-
generative and systemic diseases including Alzheimer’s,
Parkinson’s, Prion disease, and Type II Diabetes [1-3].
The misfolding of certain critical soluble proteins intro-
duces conformational changes that favor aggregation and
the creation of highly ordered beta sheet rich insoluble
polymers [4,5]. These structures, often referred to as amy-
loids in their monomeric form, or amyloid fibrils in their
long aggregated form, have been observed to accumulate
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in the brain, heart, pancreas, and other organs. They are
believed to contribute to many health problems including
memory loss, brain lesions, senile plaques, synaptic spline
loss, neurotic dystrophy, and cell death [6,7].
Considerable amount of work has been spent into
researching ways to limit the growth of amyloid fib-
rils, slow their production, and inhibit their formation.
Molecules have been designed to target early oligomer
aggregates to prevent amyloid fibril formation [8-10].
Interestingly, others have been designed to enhance fib-
ril formation to reduce the build up of oligomers in the
cases where oligomers where toxic [11]. Other approaches
included capping fibrils with docking proteins [12],
inhibiting fibrils by methods of Lysine-specific molecular
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tweezers [13], and using sulfonated triphenyl methane
derivatives as potent inhibitors [14]. Although some of
these attempts have demonstrated fibril inhibition and
slower reaction rates in vitro, the effect of introducing
these various molecules on cellular processes, reaction
pathways and other proteins is not clear and can be
unfavorable.
Amyloids have been observed to undergo mutations
that change their amyloidogenicity and rate formation.
Several cases of Parkinson’s disease are associated with
amino acid mutations of the alpha-synuclein (αS) pro-
tein [15-17]. The A30P mutation in αS decreases the
overall rate of fibril formation [18,19], while the H50Q,
H50A, and G51D mutants aggregate more quickly than
the wild type but more slowly than A53T and E46K
mutants [20]. One point mutations have been observed
to be sufficient to affect the landscape of the Aβ42 pro-
tein in Alzheimer’s and change the internal dynamics
between microstates [21]. R5A mutation studies showed
a decrease both in the tendency towards Aβ aggregate
formation and a reduced toxicity in Alzheimer’s [22]. A
mutation in amino acid position 25 of Aβ , the loop area
connecting two beta strands, has been show to desta-
bilize Aβ fibrils [23]. Furthermore, a single mutation of
serine-to-glycine at position 20 in Amylin in Chinese and
Japanese populations [24] is associated with early onset of
Type II Diabetes [25,26] and amplified amyloid formation
[27-29]. Moreover, more than 120 single point muta-
tions have been associated with the systemic disorder
FAP [30].
As a result of the heavily observed natural muta-
tions, research into deliberately mutating amino acids of
amyloids has been proposed as an explorative method
to destabilize fibrils and reduce toxicity. Computational
methods coupled and steered with Molecular Dynam-
ics runs have proved to be a viable strategy to study the
impact of mutations, however, unscalable and expensive
in resources and time [31]. Advancements in understand-
ing the effects of amyloid sequence mutations on fibril
toxicity and formation rate has paved the way for the
development of therapeutic agents to replace highly amy-
loidogenic species. Re-engineering the genetic code of
proteins and administering them as substitute agents for
patients is a promising strategy for drug development.
Pramlintide, a mutated protein version of Amylin, is used
as a drug replacement in Type I Diabetes and has been
shown to produce less fibrils and cause less beta cell
death in the pancreas [32]. It is still unclear how point
mutations alter the pathway of oligomerization and the
kinetics of fibril conformational transitions [21], however,
it is clear that proteins aggregate through nucleation-
dependent polymerization [6,20]. Hence, exploring muta-
tions that affect the nucleation of amyloid monomers
has the potential to introduce more therapeutic agents
to inhibit oligomer formation and reduce the effect of
disease.
Cross-seeding of Amylin with Amylin-derived
analogs has been shown to affect aggregation potential
[33-35]. Although cross-seedings create mixed structures
that potentially aggregate at lower rates, aggregation is
inevitable due to the preservation of amino acids or amino
acid regions on some chains that still favor aggregation.
The idea of this work is to carefully replace amino acids in
all repeating chains to create enough stress and instability
to drastically lower the aggregation potential of Amylin.
In this paper we describe a protocol to analyze the
structure of an amyloid protein and search for regions
and residues that could be exploited to weaken aggrega-
tion. We focus our study on the diabetes-related protein,
Amylin, and explore six key regions potentially contribut-
ing to amyloid oligomerization and fibril production. We
developed a tool, FibrilMutant, that implements this pro-
tocol and suggests several amino acid mutations that
weaken fibril structure. Subsequently, we address the
multi-objective problem of discovering point mutations
that destabilize fibrils yet conserve the native fold in an
efficient manner by running short Molecular Dynamics
simulations on single mutated native Amylin proteins to
detect any initial structural turbulence and utilizing a
dipolar solvent model to assess the fibril aqueous stability
of much largermutated amyloid aggregates. Our approach
generated several destabilizing mutations that respect the
multiple objectives. Oligomers and fibrils were built from
each mutation and assessed for structural stability with an
energy function that takes into account solvation energy,
hydrophobicity, electrostatic interactions, and hydrogen
bonding. We validate our method with results of muta-
tions determined experimentally for Amylin and suggest
new mutations that show stronger amyloid destabiliz-
ing potential than the current best therapeutic agent for
diabetes.
Methods
We created FibrilMutant to explore the effect of sequence
mutations on destabilizing amyloid fibrils. FibrilMutant
takes a Protein Data Bank (PDB) file of a single amyloid
monomer and a PDB file of its native protein confor-
mation as input and generates single point mutations
to destabilize the protein’s fibril structure. We apply the
mutations to both the native and the amyloid form of the
protein and calculate the stability effect on both forms.
The following procedure is followed to generate and assess
the mutations:
1. Load the PDB file into FibrilMutant and analyze key
structural characteristics contributing to aggregation.
2. Explore a set of mutations that could weaken regions
contributing to aggregation.
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3. Generate fibril stability landscapes to find the most
stable fibril polymorph of the amyloid PDBmonomer.
4. Build mutated fibrils of the most stable polymorph.
5. Assess the stability of each mutated fibril in water
with a dipolar water modal.
6. Discard any mutation that stabilizes the amyloid
fibrils, and verify with short full Molecular Dynamics
(MD) simulations that the final mutation list does
not introduce structural lump turbulences that
destabilize the native protein.
FibrilMutant builds on our recent work that enabled the
simulation of accurate fibril models [36]. Its core devel-
opment includes predicting a set of effective mutations
and building oligomers and large fibrils to test the effects
of these mutations on structural stability. A detailed
description of the procedure is described below.
Step 1: Analyzing amyloid structures
Amyloids share key structural similarities. FibrilMutant
extracts from a PDB file regions with beta strands, screens
regions at beta turns, identifies salt bridges, and examines
hydrophobic, polar and charged residues. This collected
data is then utilized to generate amino acid mutations
in the extracted key regions and residues. The protocol
followed by the algorithm in choosing destabilizing muta-
tions is outlined in Table 1. In short, for each extracted
region in the amyloid, the algorithm selects mutations that
lower the stability contribution of that region to the over-
all amyloid structure. For example, beta turns contribute
to amyloid stability by providing the needed torsional flex-
ibility for beta sheets to form. To destabilize the beta turn
regions of the amyloid, the algorithmmutates amino acids
on the beta turns into clunky prolines, causing torsional
stress and extending the torsional angles in the turns.
This causes beta strands to drift apart and weakens beta
sheet bindings. Another example is salt bridges. Some
amyloids contain salt bridges that strongly stabilize their
3-dimensional forms. If the algorithm detects a salt bridge,
it attempts to break it by mutating one of the amino acids
that contributes to the salt bridge into a non-charged,
non-polar residue. Based on our observation regarding
amyloid structure, we outlined in Table 1 six stability
regions in amyloids that could be exploited to destabi-
lize structure. In Table 2 we show the specific residues of
Amylin that belong to each stability region.
Step 2: Generating mutations
Structural data collected from an amyloid PDB file is used
to predict destabilizing mutations. The inner core of amy-
loids is known to be a hydrophobic core. One way to
disrupt this core is by introducing a mutation of one of
its amino acids into a charged residue. We have explored
several ways mutations can weaken the structure stabil-
ity of amyloids. Upon selection of potential mutations, we
run TANGO [37], a tool to estimate aggregation propen-
sity using a statistical mechanics algorithm, to quickly
rank candidate mutations and provide preliminary data
on the potential destabilizing effect of each mutation. We
understand that TANGO uses a coarse-grained model
to perform high-throughput screenings of results, hence
we only use it as a guide to initially rank the numerous
mutations.
Step 3: Fibril stability landscape
Amylin has recently been found to form into a fibril struc-
ture composed of two stacked protofibrils [38]. However,
Table 1 Effect of mutation choice on structural stability
Structure characteristic Contribution to amyloid stability Disruption method
Hydrophobic Core Hides core residues from water and generates a packed core Mutate a hydrophobic residue in the core into a
charged one
Hydrophilic Surface Provides a stable contact surface to water Mutate a polar residue on the surface into a
hydrophobic one
Beta Sheets Constitute the backbone of fibrils Decrease the number of hydrogen bonds
between Beta strands
Beta Turns Provide needed torsional flexibility for Beta sheets to form Mutate the center residue and any Glycine amino acid
of a Beta turn region into a Proline to limit torsional
flexibility
Salt Bridges Produce an ionic bond between fibril monomersor the
monomer itself
Search the amyloid structure than 4.5Å apart bonding
the following for bonds less pair of amino acids: ASP -
LYS, ASP - ARG, GLU - LYS, GLU - ARG, and mutate one
amino acid into a non charged, non polar residue to
break the ionic bond.
Polar Regions Contribute hydrogen bonds Mutate polar residues into non polar ones to weaken
hydrogen bonds
This table summarizes our approach to choosing mutations to test for fibril destabilization. We identify six main features of amyloids that contribute to structure
stability and outline the methods we used to weaken their contribution to the amyloidogenicity of proteins.
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This table outlines the residues that belong to each stability region in Amylin.
the experimental structural parameters, mainly fibril rota-
tion angle and protofibril packing distance, have not been
published yet. MD simulations could be used to find these
parameters but the process is computationally expensive
in resources and time, and we estimated these by our
previous work on Stability Landscapes [36].
Starting with an accurate crystal or NMR amyloid
monomer, we first define a range of naturally possible
values for the various fibril degrees of freedom character-
ized by rotation angles, packing distances and beta strand
proximities. Second, we utilize these range of values to
construct all possible fibril structures using rigid affine
transformations. Third, we perform light runs of Energy
Minimization (a few hundred steps of relaxing the pro-
tein structure and removing close clashing atoms) on each
generated structure to assess its initial stability sensitiv-
ity by calculating any enthalpy drift between final and
initial conformations. This step creates the fibril stability
landscape by exhausting all suitable “parameter” values.
We then search the landscape for values that construct
the most stable initial conformation. These “parameter”
values would create structures with lowest enthalpy drift
and lowest initial Lennard-Jones and Coulomb terms.
Structures with low enthalpy drifts allude to stable confor-
mations (local minima on the structural energy landscape
of fibrils), and structures with high energy drifts suggest
parameters that produce unstable conformations.
Step 4: Building fibril models
Adifferent amyloidmonomer is generated for everymuta-
tion. To test the stability effect of the mutations on fibrils,
these mutated amyloid monomers need to assemble into
fibrils. Fibrils are polymorphic and since we don’t know
the polymorph this specific amyloid protein will aggregate
in, we first need to figure out which polymorph is themost
stable for the current protein. To do this, we resort to our
previous work, CreateFibril, a tool that builds and explores
the stability of fibrils. Once we know the specific poly-
morph the protein will aggregate in, we apply mutations
to the amyloid monomer and construct a new mutated
structure with SCWRL [39]. SCWRL is a tool that deter-
mines side-chain conformations to a backbone structure.
We specified the original backbone of the protein, but
gave SCWRL the mutated sequence of amino acid to fit
onto the structure. We then perform energy minimization
on themutated structures to remove any steric clashes due
to mutations. The structure is then built into the correct
fibril polymorph by CreateFibril.
Step 5: Assessing mutated fibril structural stability
Applying point mutations to a structure can introduce
steric clashes between amino acid side chains. To com-
bat this issue, we perform Energy Minimization (EM) to
relax all mutated amyloid and native structures. After
this process of relaxation, we use our previous work to
quickly calculate the Free energy of proteins given by Eq.
(1). We calculate the LJ and Coulomb energies and use
a fast and detailed dipolar water model to compute the
solvation energy of molecules by solving the dipolar non-
linear Poisson-Boltzmann-Langevin equation. Together,
the three energy terms are used to describe the stability
behavior of fibrils. Fibrils with higher energy than the nat-
ural control are termed as unstable, and themutations that
generate them are kept for further analysis on the native
structure. We used the program AquaSol [40] with the
following setup: atomic charges and radii assigned with
PDB2PQR using CHARMM force field at neutral pH. A
grid or 257 points per edge spaced by 1 Å, a temperature
of 300K, and a solvent accessible surface with an Rprobe
of 1.4 Å. All hydrogen-bonds were optimized. We used
a trilinear interpolation protocol for projection of fixed
charges on the grid, a lattice grid size for the solvent:
a = 2.8 Å, solvent made of dipoles of moment p0 = 3.00D
at a concentration of Cdip = 55M. No salt was added to
the solution and small ions were used to equilibrate the
system when needed. The electrostatic potential was set
to zero at the boundaries, and the stopping criteria for
residual was sent to: 1.10−6 (when possible).
FE = Fsolv + Fcoulomb14 + Fvdw (1)
where,
Fsolv = F(p0,Cdip) − F(0,0) − Nwμw









Step 6: Structural deviations of the native protein
This step is crucial in addressing the multi-objective prob-
lem of discovering point mutations that destabilize fibrils
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yet conserve the native fold. Mutations that create unsta-
ble fibrils are applied to the native protein form to assess
any structural stability effect they could produce. We are
interested in mutations that destabilize the amyloid but
not the native form. Suchmutations theoretically preserve
structure and protein function and are candidates for ther-
apeutic engineering.We use SCWRL to build the mutated
native proteins and run Energy Minimization (EM) to
relax the structures.We then run a fullMD simulation and
plot RMSD and RMSF graphs to verify any structure devi-
ations caused by the mutation. In particular, we calculate
the perturbation in structural motion with
δrmsd = RMSD(mutant) − RMSD(native)
where, RMSDmeasures the root mean-square deviations,
in angstroms, of the Cα atom positions in a protein’s
residues over a simulation run.
We also calculate the root mean square fluctuations
(RMSF), a measure of the deviation between the position









where T is the total simulation time, and x˜i is the ref-
erence position of particle i. Applied to our Amylin
protein, the reference positions are the 37 amino acid
residues of the protein. The RMSF value at each residue
measures the residue’s average change in position over
the simulation run. Low RMSF values at a particu-
lar mutation site suggests the absence of local residual
instability.
Molecular dynamics and energy minimization
We used the GROMACS 4.5 [41] molecular simulation
package to run molecular dynamics (MD) and EM sim-
ulations. Our mutated proteins were solvated in a cubic
box (with a minimum distance of 35 Å from any edge of
the box to any atom) and neutralized with chloride ions
and modeled using the GROMOS96 53a6 force field along
with the SPC water model. This force field is designed
for bimolecular dynamics simulations in MD produc-
tions and handles protein structures very well [42,43]. The
force field reproduces the free enthalpies of hydration and
apolar solvation for a range of compounds, including amy-
loid proteins. We use this force field in studies involving
amyloid structures and amyloidogenicity potentials. We
used a cutoff of 10 Å for van der Waals and short range
electrostatic interactions, and calculated long range elec-
trostatic interactions using a particle mesh Ewald sum
[44,45]. Simulations were prepared for a full MD run in
both isothermal-isobaric [46] (100 ps) and canonical equi-
libration (100 ps) ensembles. Temperature and pressure
were controlled at 300 K and 1 bar using the velocity
rescaling thermostat and the Parrinello-Rahman barostat,
respectively. A linear constraint solver was used to keep
all bonds at their equilibrium length. One million time
steps were used with an integration time step of 2 fs. The
system’s coordinates were saved every 10 ps for further
analysis.
Analyzing energy results
To assess the effect of mutations on amyloid fibril sta-
bility, we generated fibril mutants up to 25 monomers
in size and used Eq. (1) to calculate their energies.
The solvation term was calculated by AquaSol while the
LJ and Coulomb terms were calculated by GROMACS.
The same formula was used in the initial assessment
of the mutated native structures. We generated RMSD
and RMSF plots from MD simulations to analyze struc-
tural changes and residue perturbations in native Amylin
mutants.
Results and discussion
In this section we apply our methods to the protein
Amylin (PDBID 2KB8 [47]), a 37 residue peptide hormone
that is secreted from the pancreas in response to intake
of food. The 2KB8 is a micelle-stabilized NMR structure
suited for diabetes protein-membrane aggregation stud-
ies. This structure is the non-amyloid form of amylin
that misfolds into amyloids. We refer to this structure
as the “native” form of Amylin throughout the remain-
ing of the paper. Amylin normally contributes to glycemic
control and inhibits the appearance of specific nutrients
in the plasma [48,49]. In patients with Type II Diabetes,
Amylin has been found to misfold into destructive amy-
loid monomers that aggregate in pancreatic beta cells and
disturb cellular activity, disrupt flow of ions throughmem-
branes, and force cells to apoptosis [50,51]. Little is known
about the mechanism or pathway behind the misfolding
event, however, the structure of Amylin’s amyloid pro-
tein is known. Patients with Type I Diabetes are unable
to produce Amylin in their pancreas and require Amylin
injections. In 2005, Pramlintide, a version of Amylin with
three point mutations that has a lower affinity to form
amyloids and fibrils was introduced in the treatment of
Type I and Type II Diabetes [52], and has been a better
substitute for Amylin in patients with diabetes. Pramlin-
tide, however, is not optimal as patients still experience
the emergence of some fibrils that further destroy their
β-cells. In this section, we present the results of applying
our FibrilMutant protocol on analyzing Amylin’s confor-
mational regions and stability landscape. Moreover, we
show that our energy function and destabilizing crite-
ria are in agreement with experimentally tested Amylin
mutations and discover novel mutations with stronger
destabilizing potential and lower fibril affinities than
Pramlintide.
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Exploring key stability regions of Amylin
The protocol we implemented into FibrilMutant identi-
fied six key stability regions in the amyloid form of Amylin
that contribute to the emergence of amyloids and the
growth of their fibrils, as shown in Table 2. We used the
PDB models devised by Wiltzius et al. from experimen-
tal data [38] that aggregate into the only observed 2-Stack
structures. FibrilMutant generated twenty three single
point mutations with potential to destabilize Amylin fib-
rils, possibly hindering their production or slowing down
their aggregation. The mutations were initially ranked by
a statistical mechanics algorithm used in TANGO [37] to
help us prioritize simulation order. Table 3 displays these
mutations. These suggested mutations imply that Amylin
amyloid fibrils are stabilized by the following four main
factors: a hydrophilic surface in contact with water, a large
hydrophobic core region, beta strands, and glycine amino
acids at beta sheet turns as illustrated in Figure 1. All pro-
posed mutations attempt to destabilize these regions to
weaken Amylin fibril structures.
Generating Amylin fibrils
To test the effectiveness of the mutations suggested by
FibrilMutant, we apply the mutations to Amylin fibrils
ranging in size from one to twenty five monomers as
shown in Figure 1. Amylin fibrils have been found to form
into a dimer conformation recently classified as a 2-Stack
[38]. Using fibril stability landscapes from our previous
work [36], we construct the mutated structures with a fib-
ril packing distance of 3.0 Å, Hbond distance of 5.0 Å
Table 3 Amylin Mutations generated by FibrilMutant with destabilizing potential
Original Residue no. Mutated Disruption TANGO
amino acid amino acid method rank
A 13 R Making core charged 1
F 15 P Mutating an amino acid on a beta strand 2
F 15 D Making core charged 3
L 16 D Making core charged 4
A 25 R Making core charged 5
I 26 R Making core charged 6
G 24 P Mutating GLY at a turn 7
L 27 R Making an amino acid on a beta strand charged 8
F 23 E Making core charged 9
G 24 D Making core charged 10
V 17 E Making core charged 11
Q 10 H Making protein surface hydrophobic 12
N 21 P Mutating an amino acid at a turn 14
C 2 Q Making protein surface hydrophobic 15
T 6 M Making protein surface hydrophobic 16
T 4 S Making protein surface hydrophobic 17
V 32 K Making an amino acid on a beta strand charged 18
N 3 H Making protein surface hydrophobic 19
A 8 E Making an amino acid on a beta strand charged 20
T 9 N Making protein surface hydrophobic 21
L 12 E making core charged 23
C 7 T Making protein surface hydrophobic 24
G 33 E Making an amino acid on a beta strand charged 25
S 20 G Discovered experimentally [29] 13
S 20 K Discovered experimentally [29] 22
N 21 L Discovered experimentally [56] 26
N 14 L Discovered experimentally [56] 27
Mutations above the horizontal line are destabilizing mutations proposed by FibrilMutant, and mutations below the line have been suggested and tested
experimentally. Mutations are ranked by TANGO from lowest aggregation potential to highest aggregation potential.
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Figure 1 Amylin amyloids. Left: Identification of key stability regions of amyloid Amylin by FibrilMutant. Beta strands are colored green, beta turns
red, charged residues orange, hydrophobic residues purple, polar residues grey, and glycine residues at turns blue. Right: Full Amylin fibrils of 25
monomers in size.
between monomers and a rotation angle of 9 degrees
along the fibril axis. Each fibril contains one amino acid
mutation on each of its amyloid monomers. The stabil-
ity landscapes are efficient-exhaustive search heuristics
for structural parameters that create energetically optimal
fibril shapes.
Analyzing Amylin fibrils
Figure 2 shows the free energies of the most significant
fibrils at their nucleation phase and at their extended
aggregation phase. Energy values higher than the control
fibril correspond to a decrease in stability, while lower
energies correspond to an increase in fibril stability. We
are interested in mutations that create the most insta-
bility. To be able to sort out these better mutations, we
developed three formulas to rank the mutations accord-
ing to themetrics that measure a protein amyloidogenicity
factor, a fibril nucleation factor, and a fibril aggregation
extension potential factor. Together, these metrics are
intended to measure stability deviations in the various
stages of fibril development and growth. We measure the
amyloidogenicity factor by
Gi = Fia1 − Fn1 (2)
where Gi is the free energy resulting from transform-
ing an Amylin protein from a mutated native to a mutated
amyloid fold, Fia1 is the free energy of a single amyloid
monomer and Fn1 is the free energy of a single native
protein for all mutated fibrils i.
The second metric is
Ni = Fia4 − 4 Fia1 (3)
where Ni is the free energy of nucleation resulting from
joining four free amyloid monomers into a fibril structure,
Fia4 is the free energy of an Amylin fibril composed of 4
monomers and Fia1 is the free energy of a single amyloid
monomer for all mutated fibrils i.
The thirdmetric,F˜ i, measures the difference in energy
between the mutated fibril and the control averaged out
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Figure 2 Free energies of Amylin mutated fibrils calculated with Eq. 1. The inner box is a close up showing energies at the nucleation phase. The
control wild type fibril is marked with boxes along its curve. All fibrils with lines above the control are less stable than the control, and all fibrils below
the control increase fibril stability.
where Fiaj is the free energy of the mutated fibril i at length
j and Fcaj is the free energy of the control wild type fibril at
length j.
Together, G,N and F˜ provide insights into the sta-
bility perturbations caused by the mutations at the amy-
loid formation phase, fibril nucleation phase, and fibril
elongation phase, respectively. Figure 3 shows the energy
values of all the three metrics applied to the mutated
fibrils. A positive G value describes an endothermic
reaction where native Amylin structures required an input
of energy to form into amyloid monomers. The higher the
G, the higher the gap in energy between amyloids and
native Amylin. Negative G suggest favorable exothermic
reactions and possibly spontaneous formation of fibrils.
Hence, mutations in Figure 3 with negative G are elimi-
nated in red.
N is useful in comparing the strength of fibrils cre-
ated at nucleation. The more negative N values produce
stronger exothermic reactions, and hence more stable fib-
rils. For our study, we want to explore the mutations
that produce a Ni greater than Nc (control). We rank
the mutations in the middle column of Figure 3 from
weakest to highest and remove all mutations smaller than
Nc. Finally, F˜ i estimates the stability deviation of the
mutated fibril from the control wild type. Positive values
suggest fibrils that are weaker than the control and nega-
tive values suggest fibrils more stable than the control. We
observe that the energy gap widens between fibrils and the
control as fibrils grow in size which suggests that unstable
fibrils (high energy difference with respect to the control)
are likely to create energetically preferred shorter struc-
tures, possibly a better chance for degrading enzymes and
macrophages to destruct them [53,54]. We ranked the fil-
tered mutations in Figure 3 and highlighted in green the
unstable fibrils out of our set.
The sensitivity of amyloid formation to point mutations
can be exploited to design slower and shorter Amylin
aggregating variants which cells might be able to discard.
There has been no reported systematic analysis of all of
the amino acid positions of IAPP or their amyloidogenic-
ity potential, and mutation studies are sparse [55]. We
validate our method and rankings by first considering the
few mutations explored experimentally [29,56]. Amylin
N14L and N21L mutants did not form amyloids experi-
mentally while, the S20Kmutant lengthened the lag phase
by a factor of 18 and had a significant effect on amyloid
formation and S20G was observed to form amyloids. The
lower part of Figure 3 shows the G, N , and F˜ of
these 4 mutations. We observe that N14L and N21 have
a higher N and F˜ than the control, suggesting that
these mutations destabilize their fibrils, and hence could
explain why they do not form experimentally. S20K has a
N that is also higher than the control, suggesting that
the nucleation product is less stable than the control’s
oligomer, also suggesting a longer nucleation phase as
observed experimentally. The S20KF˜ is quite small, sug-
gesting that this mutation might form unstable fibrils, as
observed experimentally. The S20G mutant was observed
to form amyloids, and its corresponding F˜ also suggests
this finding. It is key to note that Pramlintide ranked as
the highest unstable mutant explored experimentally with
a F˜ = 436.84, close in instability to the N21L mutant.
Our results indicate that the mutant L12E causes the
most instability to fibrils and has a high G, N , and F˜ .
Smaoui and Waldispühl BMC Structural Biology  (2015) 15:7 Page 9 of 12
Figure 3 Stability values of mutated fibrils. Mutations above the
horizontal line were proposed by FibrilMutant. Mutations below the
line were explored experimentally. The “Control” fibril is the
non-mutated, naturally occurring fibril. Units are in KCal/mol.
In fact, its F˜ is more than twice as large as the PRAM
F˜ , suggesting that it might inhibit fibrils altogether. The
mutant A8E also has twice as large a F˜ than PRAM, but
also has a slower more unstable nucleation phase, indicat-
ing that it has a strong potential to inhibit fibril formation.
In fact, the results of running AmyloidMutants [57] on the
A8E mutation suggest that this point mutation destabi-
lizes amylin fibrils, as shown in Additional file 1: Figure S1.
The last competitive mutant, G33E, also exhibits a higher
F˜ than Pramlintide and shows a highN value, also sug-
gesting high instability in the nucleation phase and fibril
elongation phase. Together, these observations recom-
mend a Glutamic acid mutation in Amylin to stop it from
forming fibrils. Since Amylin contains no acidic residues,
the addition of this charged, acidic residue will enhance
the formation of a quasi-infinite array that destabilized
the fibrils with unfavorable electrostatic interactions cre-
ated along the fibril length [29]. The other highlighted
mutations in green in Figure 3 also have the potential to
destabilize and inhibit fibrils, and their effect might be
similar or smaller than Pramlinitide. Although the energy
plots in Figure 2 suggest that destabilizing mutations con-
tinue to show an increase in fibril stability as aggregation
increases, this doesn’t necessarily mean that aggregation
will happen. The instability introduced by the mutations
could increase the activation energy beyond the physi-
ological means required for misfolding and aggregation
to occur. An excellent example is rat Amylin; it contains
three mutations that increase the instability of its amyloid
fibrils and hinder it form aggregating in vivo. However,
under the right environment conditions, the aggregation
of rat Amylin into long fibrils can still occur [58]. Nev-
ertheless, the three destabilizing mutations introduced
enough instability to create an activation barrier that is
difficult to surpass in physiological conditions. The results
we report in this study are important to design stronger
alternative variants to the Pramlintide antihyperglycemic
drug with a minimalistic mutation approach for diabetes
patients.
TANGO and AmyloidMutants are current computa-
tional tools exploring amyloid stability and analyzing the
effect of secondary structure modifications on increas-
ing amyloidogenicity and protein aggregation. Such tools
use coarse-grained models that enable them to per-
form high-throughput screenings, but cannot achieve
the accuracy of higher resolution models [31]. The use
of AmyloidMutants and TANGO assisted in ranking
candidate destabilizing mutations prior to running our
computationally expensive dipolar solvent model to accu-
rately assess the instability caused in the mutated fib-
rils. Although the TANGO and AmyloidMutants results
did not match well with our results, they did provide
some valuable insight. TANGO results in Additional file
1: Table S1 suggest that the A8E mutation doubles the
potential of alpha helices compared to the Control and
the L12E mutation lowers the amyloidogenicity by a fac-
tor of 42 compared to the Control. AmyloidMutants
also suggested that the A8E mutation should destabilize
fibrils.
Maintaining native structure & function
Introducing a mutation to the sequence of Amylin might
cause a change in its structure and force it to fold into
a different shape, affecting its normal function. For this
reason, we have tested the effect of the destabilizingmuta-
tions on the native structure of Amylin. The free energies
of mutated Amylin in Figure 4 show that the mutations
result in energy states close to the native control, rat
Amylin, and pramlintide. Figure 4 suggests that these
mutations do not make native Amylin unstable. To fur-
ther verify this, we ran 20 ns MD simulations on the
top 3 native mutants (L12E, A8E, and G33E) to test any
structural turbulence or major energetic imbalances as a
result of the point wise substitutions. We observed very
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Figure 4 Stability of the Amylin mutants in their native fold. Each bar
represents one mutated protein in native fold, where the energies are
the free energy differences between the mutant and the
non-mutated Amylin.
slight deviations in δrmsd , stable RMSF in mutated regions
and smooth energy trajectories, suggesting a preservation
in shape and function. Figure 5 shows the δrmsd and
RMSF results for best mutants, L12E, A8E, and G33E.
Although the simulation time that was used does not pro-
vide a definitive conclusion on the stabilities of the three
mutants, the δrmsd and RMSF results point towards native
confirmation stability.
Conclusion
The process of amyloid protein formation and aggrega-
tion is sensitive to amino acid sequence point mutations.
We discuss in this manuscript how altering the genetic
code of these amyloid proteins has been shown to affect
fibril stability, monomer propagation and growth (see
Figures 2, 3 and 4). The RMSD and RMSF molecular
dynamics results in Figure 5 simulate the change in the
shape of the mutant amyloid structures during the pro-
cess of aggregation, which can have a direct effect on
the infectivity and toxicity of fibrils. The less stable a
fibril structure becomes, the higher the potential for a
decrease in toxicity. Certain regions in amyloid proteins
contribute to fibril structural stability, compactness, and
insolubility. Altering some amino acids that make up these
regions, such as the amino acids that are involved in cre-
ating a hydrophobic core, can create energy perturbations
and imbalances that weaken an individual amyloid pro-
tein monomer and subsequently carry on the effect to
weaken every amyloid monomer on the fibril, resulting
in an accumulated fibril destabilization effect. Destabiliz-
ing one amyloid form can potentially lead it to aggregate
into a different form. Since the current Amylin form is
a 2-Stack (dimer amyloid), we assume in this work that
the destabilization would weaken the 2-Stack structure.
It is possible that the 2-Stack separates into single lin-
ear amyloid aggregates. However, it is unlikely that the
destabilized 2-Stacks form into tri-mers (3 connected lin-
ear strands). For this reason, it is important to examine
the resulting destabilizing set of mutations and experi-
mentally select those that cause instability to the core of
Figure 5 δrmsd and RMSF plots for mutants L12E, A8E, and G33E over a 20ns simulation. The top figures display δrmsd graphs between each mutant
and the native Amylin, and the bottom plots are the RMSF plots. (a)Mutant L12E shows a δrmsd < 1.2 and an RMSF < 0.6 at residue 12, (b)mutant
A8E exhibits a δrmsd < 1.1 and RMSF < 0.5 at residue 8, and (c)mutant G33E has a δrmsd < 1 and an RMSF < 1 at residue 33. δrmsd and RMSF results
show extremely small modifications in structure and minimal structural variance at the amino acid mutation sites.
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the protein, rather than causing instability on the con-
tact surface holding 2-Stack structures together. Tackling
the problem from this perspective has enabled us to com-
putationally perform an amino acid mutation analysis on
Amylin to unravel modifications that potentially destabi-
lize fibrils, yet are restricted to conserve the native fold
of the protein. Addressing this multi-objective problem
can be generally useful in suggesting novel therapeutic
agents or improving existing treatments for cases where
drugs have to be administered to patients. In our case,
addressing this problem has opened up discussions on the
3 potential efficacy improvements in the Pramlintide drug
for Diabetes.
Additional file
Additional file 1: Supplementary material. Figure S1. presenting a
simulation of AmyloidMutant on the 3 mutations. Table S1. showing a run
of TANGO of the mutations we tested.
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